MiniMed (MMED) Research & Development (2025 - 2026)
MiniMed (MMED) posted Research & Development of $99.0 million for Q2 2026, down 13.16% on a QoQ basis from $114.0 million in Q1 2026, and down 7.48% year-over-year from $107.0 million in Q2 2025.
MiniMed (MMED) Research & Development (2025 - 2026) Analysis & Trends
MiniMed's Research & Development history runs 2 years deep, the most recent figure standing at $99.0 million for Q2 2026.
- Quarterly Research & Development fell 7.48% year-over-year to $99.0 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $432.0 million (changed N/A YoY) and the FY2026 annual result came in at $448.0 million, up 2.75% from the prior year.
- Research & Development was $99.0 million for Q2 2026 at MiniMed, down from $114.0 million in the prior quarter.
- Across five years, Research & Development topped out at $114.0 million in Q1 2026 and bottomed at $99.0 million in Q2 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 31.90 Bn | 24.59 Bn | 662.02 Mn | 208.32 Mn |
| 2 | BrightSpring Health Services | 14.63 Bn | 13.73 Bn | 482.22 Mn | - |
| 3 | Healthequity | 8.31 Bn | 8.04 Bn | 256.31 Mn | 26.83 Mn |
| 4 | Hinge Health | 5.95 Bn | 5.64 Bn | 154.23 Mn | 30.34 Mn |
| 5 | 10x Genomics | 5.84 Bn | 5.30 Bn | 106.18 Mn | 56.85 Mn |
| 6 | Waystar Holding | 4.49 Bn | 4.42 Bn | 216.84 Mn | 45.83 Mn |
| 7 | MiniMed | 4.47 Bn | 4.17 Bn | 480.00 Mn | 99.00 Mn |
| 8 | Doximity | 3.96 Bn | 3.22 Bn | 125.97 Mn | 39.11 Mn |
| 9 | Privia Health | 3.18 Bn | 2.76 Bn | - | 8.13 Mn |
| 10 | Omnicell | 1.86 Bn | 1.62 Bn | 140.36 Mn | 21.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 24, 2026 | 99.00 Mn |
| Jan 23, 2026 | 114.00 Mn |
| Apr 25, 2025 | 107.00 Mn |
| Jan 24, 2025 | 112.00 Mn |